Dr. Strain is the Director of the Johns Hopkins Center for Substance Abuse Treatment and Research and the Executive Vice Chair for Psychiatry at Johns Hopkins Bayview Medical Center. He maintains an active research program in substance abuse related issues, provides clinical care to patients, teaches medical students and residents, and provides administrative supervision in the maintenance of current substance abuse programs and the development of new substance abuse initiatives at Johns Hopkins. In addition to his responsibilities at Johns Hopkins, Dr. Strain chairs the NIH ARM study section, is the Editor in Chief for the journal Drug and Alcohol Dependence, and is on the editorial board for several other journals. He edited, with Maxine Stitzer, the books Methadone Treatment for Opioid Dependence and The Treatment of Opioid Dependence, and with Pedro Ruiz edited the fifth edition of Lowinson and Ruiz’s Substance Abuse: A Comprehensive Textbook. He was the lead in developing the first buprenorphine curriculum, which has been subsequently used as the primary resource to train physicians in the use of this medication for the treatment of opioid dependence. He was Chair of the Food and Drug Administration's Drug Abuse Advisory Committee, and the American Psychiatric Association’s Council on Addiction Psychiatry. He has served on the boards of The College on Problems of Drug Dependence (for which he was President), the American Academy of Addiction Psychiatry, and Baltimore Substance Abuse Systems. He also has served on various committees for the National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism, and the federal Center for Substance Abuse Treatment, and is a frequent reviewer for scientific journals in the area of substance abuse. Dr. Strain is the recipient of several competitive grant awards from the National Institute of Health, and has published extensively on substance abuse-related matters. His research areas have included topics such as the optimal mechanisms for treating patients with substance abuse disorders, including opioid and cocaine dependence, the relationship between substance abuse and other psychiatric disorders, the abuse liability of novel medications, and the development of new pharmacotherapies for substance abuse treatment (including opioids and alcohol). His studies have included medications such as buprenorphine, methadone and LAAM, pharmacotherapies for alcohol dependence, and non-pharmacologic treatments for substance abuse disorders.